Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • survival analysis
AI-Driven Prognosis: EEGSurvNet Accurately Predicts Seizure Timing From Routine EEG Data
Posted inAI Neurology news

AI-Driven Prognosis: EEGSurvNet Accurately Predicts Seizure Timing From Routine EEG Data

Posted by MedXY By MedXY 01/28/2026
Researchers developed EEGSurvNet, a deep survival model that analyzes routine EEG to predict seizure risk over two years. Outperforming clinical models, it achieved an AUROC of 0.80 at two months and showed high efficacy in patients without visible epileptiform discharges.
Read More
Integrating Local and Metastasis-Directed Therapies Redefines Survival in Oligometastatic Prostate Cancer: Evidence from an Umbrella Review
Posted innews Oncology Urology

Integrating Local and Metastasis-Directed Therapies Redefines Survival in Oligometastatic Prostate Cancer: Evidence from an Umbrella Review

Posted by MedXY By MedXY 01/08/2026
An umbrella review of 21 meta-analyses involving 160,000 patients confirms that prostate radiotherapy and metastasis-directed therapy significantly improve survival and progression control in oligometastatic prostate cancer, establishing a new multimodal standard of care.
Read More
Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy
Posted innews Oncology

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy

Posted by MedXY By MedXY 10/28/2025
Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making.
Read More
Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained
Posted inClinical Updates news Oncology Specialties

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

Posted by MedXY By MedXY 08/06/2025
This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.
Read More
  • Time-Varying Risks in Colorectal Adenoma Recurrence: Why Histology and Demographics Demand a Personalized Surveillance Calendar
  • Scalable Telephone-Based Behavioral and Mindfulness Interventions Effectively Reduce Long-Term Loneliness in At-Risk Older Adults: Insights from the HEAL-HOA Trial
  • Over 50% of Publicly Insured Children Face Neurodevelopmental Disorders Following Infant Heart Surgery
  • Evidence-Based Impact: How EDI Initiatives are Reshaping the Healthcare Workforce
  • Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in